Vaccines

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

Five things for pharma marketers to know: Tuesday, January 20

Five things for pharma marketers to know: Tuesday, January 20

By

FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Gates Foundation sponsors campaign to promote vaccinations

The artwork is meant to inspire debate and donations for vaccinations.

Five things for pharma marketers to know: Tuesday, January 6

Five things for pharma marketers to know: Tuesday, January 6

By

Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.

GSK shingles vax shaping up to compete with Merck's

GSK shingles vax shaping up to compete with Merck's

By

The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.

Pfizer urges parents to take the pledge against meningitis

Pfizer urges parents to take the pledge against meningitis

By

Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.

Five things for pharma marketers to know: Monday, December 1

Five things for pharma marketers to know: Monday, December 1

By By

GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, August 28

By

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

Endorsement could boost Pfizer vax

Endorsement could boost Pfizer vax

By

It could also eat into Merck's Pneumovax sales.

EU mulls new Prevnar 13 indication

A greenlight could garner Pfizer $1B in sales.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.

Study finds delaying vaccines is risky

Study finds delaying vaccines is risky

By

A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.

CDC: un-vaccinated behind measles outbreak

The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

By

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

Study: Anti-vaxxers immune to PSAs

Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.

Prevnar 13 hits goals, but impact is uncertain

Prevnar 13 hits goals, but impact is uncertain

By

Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.

Study shows HPV vax impact

Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.

Doctors say vaccines don't pay

Ten percent of surveyed doctors told the Centers for Disease Control that reimbursement rates are not enough.

Pfizer Prevnar data could boost Rx numbers

Pfizer Prevnar data could boost Rx numbers

By

The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.

Merck sends HPV vax to FDA

Merck sends HPV vax to FDA

By

The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.

Panel urges increased HPV vaccination rates

Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.

Lilly primes investors for possible cuts

Lilly primes investors for possible cuts

By

Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.

Shutdown dims lights at FDA, NIH and CDC

Shutdown dims lights at FDA, NIH and CDC

By

The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.

Merck reorg reimagines sales force

Merck reorg reimagines sales force

By

The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.

Kleenex brand goes flu hunting

Kleenex brand goes flu hunting

By

The Kimberly-Clark-backed cold and flu predictor mixes Big Data, and big branding, with an individualized focus.

GSK clears another flu vaccine, but patients may not be buying

GSK clears another flu vaccine, but patients may not be buying

By

The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.

Business briefs: GSK, Otsuka, Roche and Gilead

GSK seeks a new ovarian cancer indication for Votrient; a bill that would extend exclusivity for some combination drugs is introduced in Congress; Otsuka's tolvaptan gets a thumbs-down from an FDA advisory committee; NICE rejects Roche's Perjeta; India tosses Herceptin patents; and China revokes Gilead's patent on Viread

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.

Email Newsletters